Similar articles

• The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.

  Mameli C, Galli E, Mantegazza C, Fabiano V, Zuccotti GV. Mameli C, et al. Future Microbiol. 2015;10(10):1579-98. doi: 10.2217/fmb.15.91. Epub 2015 Oct 6. Future Microbiol. 2015. PMID: 26437903 Review.
• Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data.

  Harcourt S, Morbey RA, Bates C, Carter H, Ladhani SN, de Lusignan S, Smith GE, Elliot AJ. Harcourt S, et al. Vaccine. 2018 Jan 25;36(4):565-571. doi: 10.1016/j.vaccine.2017.11.076. Epub 2017 Dec 13. Vaccine. 2018. PMID: 29246475
• A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).

  Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. Prymula R, et al. Hum Vaccin Immunother. 2014;10(7):1993-2004. doi: 10.4161/hv.28666. Hum Vaccin Immunother. 2014. PMID: 25424809 Free PMC article. Clinical Trial.
• Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.

  Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, Clark SA, Findlow J, Pizza M, Ramsay ME, Ladhani SN, Borrow R. Parikh SR, et al. Lancet Infect Dis. 2017 Jul;17(7):754-762. doi: 10.1016/S1473-3099(17)30170-6. Epub 2017 Mar 30. Lancet Infect Dis. 2017. PMID: 28366725
• Meningococcal B Vaccination (4CMenB) in Infants and Toddlers.

  Esposito S, Tagliabue C, Bosis S. Esposito S, et al. J Immunol Res. 2015;2015:402381. doi: 10.1155/2015/402381. Epub 2015 Aug 17. J Immunol Res. 2015. PMID: 26351647 Free PMC article. Review.